Yes. We keep the HL7 and DICOM interfaces that move MRI and amyloid PET studies between imaging centers, PACS, and your EHR reliable and monitored. This matters most for anti-amyloid therapies like lecanemab, where ARIA monitoring requires serial surveillance MRIs on a strict schedule that cannot slip because of a broken interface. We work with your imaging vendors and radiology partners so studies are available to neurologists and infusion teams as soon as they are read. If an interface fails, our monitoring flags it and we respond before it delays care.